Global Neoantigen Cancer Vaccine Market is expected to grow at a 20.0% CAGR during the forecast period for 2025-2034.
Neoantigen Cancer Vaccines are vaccines that assist in boosting the immune system by using a single or several antigens. The antigens generally consist of several peptides or proteins. Neoantigens are a mutated or a new type of antigen present only in cancer cells and not in rest normal cells. Neoantigen Cancer Vaccines stimulate the new T-cell response against the mutated antigens present in the cancer cells.
Neoantigen Cancer Vaccine has recorded with proven effectiveness and satisfactory results in clinical trials test of cancer treatment. Increasing cases for cancer patients across the globe and rising focus on specific & effective cancer management treatments are propelling the demand for oncology drugs and apparently boosting the market for global Neoantigen Cancer Vaccine market. Increasing emphasis on personalized cancer treatment and rising economic burden due to cancer treatment procedures has led the pharmaceutical manufacturers to invest significantly in research and development activities in order to fulfil the existing as well as latent demand for Neoantigen Cancer Vaccine.
The neoantigen cancer vaccines market is segmented on the basis of product, neovaccine type, therapy type, and region. Based on the products, the market is divided into Personalized neoantigens vaccines and Off-the-shelf Neoantigen vaccines. On the basis of neovaccine type, the market is segmented into Nucleic acid/DNA/mRNA Vaccine, Peptide Vaccines, and Dendritic Cell-based Vaccines. Based on region, the market is studied across North America, Asia-Pacific, Europe, and the Rest of World. North America is expected to dominate the market during the analysis of the forecast period.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 20.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, By Neovaccine Type, By Therapeutic Area By Therapy Type |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Moderna Therapeutics/Merck, Advaxis, Agenus, Genocea Biosciences Inc, Gritstone Oncology, Neon Therapeutics, Nouscom, OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, Vaccibody, Brightpath Biotherapeutics, Geneos Therapeutics, Frame Therapeutics, Immunetune, NeoPhore, and CureVac AG., and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Neoantigen Cancer Vaccine Market by Product

Global Neoantigen Cancer Vaccine Market Based on Neovaccine Type
Global Neoantigen Cancer Vaccine Market Based on Therapy Type
Global Neoantigen Cancer Vaccine Market Based on Region
Europe Neoantigen Cancer Vaccine Market Outlook,
North America Neoantigen Cancer Vaccine Market Outlook,
Asia Pacific Neoantigen Cancer Vaccine Market Outlook,
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.